treatment for infertility
Scope
Date
~
-
Bio & Pharma
Hanmi's Rolvedon set to post $10 mn in Q4 net sales in US
South Korean drugmaker Hanmi Pharmaceutical Co.’s neutropenia agent, Rolvedon (eflapegrastim-xnst), is forecast to achieve about $10 million i...
Feb 02, 2023 (Gmt+09:00)
-
Bio & Pharma
Bridge Biotherapeutics, Pinotbio develop lung cancer treatment
South Korea's biotech companies Bridge Biotherapeutics Inc. and Pinotbio on Thursday said they will jointly develop new antibody-drug conjugates (AD...
Jan 27, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N to introduce biosimilars for bone disease treatment from Spain
South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to intr...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Inventage Lab launches clinical trials for addiction treatment in Australia
South Korea's Inventage Lab, a developer of a drug delivery system platform, on Wednesday said it received approval from the Human Research Ethics C...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
ST Pharm exports $14.6 mn worth of drug ingredients to Europe
ST Pharm Co., a South Korean company specializing in contract development and manufacturing of drug ingredients, has signed a supply contract worth ...
Jan 20, 2023 (Gmt+09:00)
-
Bio & Pharma
LG Chem completes acquisition of US biotech firm AVEO
LG Chem Ltd. is set to complete its $571 million purchase of the US biotech firm AVEO Pharmaceuticals Inc. on Friday, which would strengthen its ant...
Jan 19, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma's Sanfilippo treatment eligible for FDA priority review
GC Biopharma Corp. said on Wednesday that its Sanfilippo type A treatment, which is under joint development with Novel Pharma, a bio-venture special...
Jan 18, 2023 (Gmt+09:00)
-
Bio & Pharma
MedPacto's anti-cancer substance designated as US FDA fast-track item
South Korean biotech company MedPacto Inc. ’s Vactosertib monotherapy for osteosarcoma patients has been designated as a fast-track developmen...
Jan 18, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma
Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...
Jan 16, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Chemicals launches uremia itching treatment tablet
SK Chemicals said on Monday that it has launched Remitch in orally disintegrating tablets, a treatment for intractable uremic pruritus (uremia itchi...
Jan 16, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N gets approval to sell K-CAB in Singapore
South Korean biohealth company HK inno.N said on Wednesday that it has received an item approval for K-CAB, a new drug for gastroesophageal reflux d...
Jan 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Prestige Biopharma attains patent for solid cancer treatment antibody
Prestige Biopharma Korea said on Tuesday that it has obtained a domestic patent for the CTHRC1 neutralizing antibody of the drug candidate PBP1710. ...
Jan 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Kolon signs MOU with Hanyang Univ. to develop gene therapy treatments
Kolon Industries Inc.'s Future Technology Institute said on Thursday that it had signed a memorandum of understanding with the Hanyang University In...
Jan 05, 2023 (Gmt+09:00)
-
Bio & Pharma
NeoImmuneTech, US think tank to develop treatment for acute radiation syndrome
Biopharmaceutical company NeoImmuneTech has grabbed an opportunity to supply new drug candidates in development as strategic items to the US gover...
Jan 04, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion's Remsima receives approval in 100 countries in 10 years
South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) h...
Jan 03, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB confirms ophthalmic disease treatment in phase 3 clinical trials
South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effectiv...
Jan 03, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Chemicals introduces Tiglutik, treatment for Lou Gehrig's disease
SK Chemicals said on Monday that it is strengthening its portfolio of neurological diseases by introducing Tiglutik (riluzole), Lou Gehrig's disease...
Jan 02, 2023 (Gmt+09:00)
-
Bio & Pharma
CJ applies to FDA for trials of immuno-anticancer drug candidate
CJ Bioscience, an independent red bio (pharmaceutical and healthcare) subsidiary of CJ CheilJedang Corp., said on Monday it has submitted a phase 1 ...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
CENYX Biotech, developing treatment for brain damage with ROS-scavenging, nano-sized heavy metals
When severe brain diseases such as cerebral infarction or cerebral hemorrhage occur, the blood-brain barrier (BBB) in our body no longer functions p...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
LegoChem Bio, Amgen sign ADC platform deal for up to $1.2 bn
South Korean pharmaceutical firm LegoChem Biosciences Inc. said on Dec. 23 it has transferred the antibody-drug conjugates (ADC) technology platform...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for FDA approval for Remsima SC
Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
ToolGen, ANLBIO to jointly develop progeria treatments
South Korea's two biotech startups ToolGen Incorporated and ANLBIO on Tuesday signed a joint research and development agreement for developing proge...
Dec 21, 2022 (Gmt+09:00)
-
Bio & Pharma
JW Pharma applies for phase 3 trial in Taiwan for gout treatment
JW Pharmaceutical announced through its disclosure on Monday that it had applied last Friday for a phase 3 trial for Epaminurad, a gout treatment, w...
Dec 19, 2022 (Gmt+09:00)
-
Bio & Pharma
LG Chem in $95.5 million drug out-licensing deal with China’s Innovent
LG Chem Life Sciences, the biopharmaceutical unit of LG Chem Ltd., and China’s biotech company Innovent Biologics have entered into a strategi...
Dec 15, 2022 (Gmt+09:00)
-
Bio & Pharma
S. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer
South Korea's GI Cell, the cell therapy affiliate of GI Innovation, on Tuesday said it signed an agreement with Optieum Biotechnologies of Japan on ...
Dec 14, 2022 (Gmt+09:00)
-
Bio & Pharma
LG Chem confirms diabetes drug Zemidapa's efficacy in phase 3 trials
LG Chem Ltd. announced in a disclosure on Monday that it had confirmed superior efficacy in phase 3 clinical trials for the combined administration ...
Dec 13, 2022 (Gmt+09:00)
-
Bio & Pharma
SK Biopharmaceuticals launches epilepsy drug in France
South Korean SK Biopharmaceuticals Co. said on Friday that its treatment of epilepsy "Cenobamate" has been approved for sale in France.The company l...
Dec 09, 2022 (Gmt+09:00)
-
Bio & Pharma
Orion to enter dental disease treatment sector
Orion Corp., the Korean company, best known for its signature product choco pie, is entering drug development. Instead of indirectly running a joint...
Nov 30, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins trial against Regeneron for US patent lawsuit over biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced Friday that it won its first trial against New York-based biotech giant Regeneron Ph...
Nov 18, 2022 (Gmt+09:00)
-
Waste management
BKT thrives as lone Korean wastewater treatment provider in US
South Korean water treatment provider Bukang Tech(BKT) on Wednesday said it earned a contract to build a wastewater treatment facility in the US sta...
Nov 18, 2022 (Gmt+09:00)
Latest News
- 1 Hyundai, Waymo forge multi-year, strategic partnership for self-driving vehicles
- 2 AI startup MarqVision raises $16.5 mn to close Series A
- 3 Taihan Cable wins $630 mn power grid project in Singapore
- 4 Korean startup scene is gloomy, say 2 out of 5 startup CEOs
- 5 MBK ups stakes for Korea Zinc to match buyback offer